Gemini Bioproducts Acquires ORFLO Technologies

Cell Microsystems Acquires Fluxion Biosciences

August 23, 2023

Medical Devices

Durham-based Cell Microsystems has acquired Fluxion Biosciences, adding Fluxion's IonFlux, BioFlux and IsoFlux instruments and services to its CellRaft-based product portfolio. The deal is supported by a concurrent Series B financing led by Telegraph Hill Partners to provide growth capital and accelerate product and service integration for cellular analysis and electrophysiology workflows.

Gilead Sciences Acquires MiroBio

September 20, 2022

Biotechnology

Gilead Sciences completed the acquisition of U.K.-based biotechnology company MiroBio for approximately $405 million in cash. The deal gives Gilead MiroBio's discovery platform and portfolio of immune inhibitory receptor agonists, including lead investigational antibody MB272, which is in Phase 1 clinical trials.

Illumina Acquires Fluent BioSciences

July 9, 2024

Biotechnology

Illumina, Inc. has acquired Fluent BioSciences to integrate Fluent's PIPseq single-cell technology into Illumina's product portfolio and accelerate its multiomics capabilities. The acquisition, which closed July 9, 2024 and was funded with cash on hand, brings Fluent's accessible, scalable single-cell chemistry and the Fluent team into Illumina to expand end-to-end single-cell solutions for research and applied customers.

Agomab Therapeutics Acquires Origo Biopharma

December 15, 2021

Biotechnology

Agomab Therapeutics NV has completed the acquisition of Spanish biotech Origo Biopharma, integrating Origo's team and facilities in Touro and Barcelona into Agomab's organization. The deal combines Origo's organ‑restricted small‑molecule platform targeting the TGF‑β pathway with Agomab's HGF‑targeting antibody programs to broaden the combined clinical‑stage pipeline for fibrosis therapeutics.

Saint-Gobain Life Sciences Acquires Equflow B.V.

September 2, 2021

Medical Devices

Saint-Gobain Life Sciences has acquired Equflow B.V., a Netherlands-based designer and manufacturer of flowmeters and sensors serving the single-use bioprocessing market. The acquisition expands Saint-Gobain's Bio-Process Solutions product capabilities and single-use fluid management offerings.

Cyrus Biotechnology Acquires Orthogonal Biologics and Raises $18M Series B

December 6, 2021

Biotechnology

Cyrus Biotechnology completed an acquisition of Orthogonal Biologics and closed an $18 million Series B financing to build an integrated software-and-screening pre-clinical biologics discovery firm. The financing was led by a syndicate including OrbiMed Advisors, Trinity Ventures, Agent Capital and other investors, with Selecta Bioscience joining as a strategic investor; the acquisition brings Orthogonal’s deep mutational scanning protein engineering capabilities into Cyrus’s computational discovery platform.